60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
WASHINGTON, Feb. 08, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has appointed Kristen Landon to the newly created role of Chief Commercial Officer, effective immediately. Ms. Landon is an accomplished commercial leader with over 26 years’ experience launching, building, and transforming commercial teams and brands in the pharmaceutical industry.
Related news for (SXTP)
- 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering
- 24/7 Market News Snapshot 15 July, 2025 – 60 Degrees Pharmaceuticals, Inc. Common Stock (NASDAQ:SXTP)
- 60 Degrees Pharmaceuticals Targets Human and Canine Babesiosis Markets With Tafenoquine
- Today’s Top Performers: MoBot’s Market Review 07/15/25 07:00 AM
- 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion